Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
NCT06408935
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan at Week 48.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Center for Colitis and Crohns Disease University of California, San Francisco, California +72 locations
Conditions: Crohn's Disease
Register for Updates
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
NCT05984927
Recruiting
This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD).
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
08/18/2025
Locations: Cincinnati Eye Institute, Cincinnati, Ohio +4 locations
Conditions: Age-Related Macular Degeneration
Register for Updates
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
NCT06581432
Recruiting
This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2. Participants are put into 13 groups based on the type of advanced cancer and the type of HER2 alterations they have.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Alaska Oncology and Hematology, LLC, Anchorage, Alaska +66 locations
Conditions: Solid Tumours
Register for Updates
BoneTape Feasibility Trial
NCT06600854
Recruiting
This study aims to evaluate the safety, effectiveness, and usability of BoneTape, an innovative medical device designed to fix facial bone fractures, specifically in the zygomaticomaxillary (midface) region. Zygomaticomaxillary fractures, often caused by trauma like car accidents or falls, require surgery to align and stabilize the bones for proper healing. Traditional methods use metal plates and screws, which can be complicated to install, over-engineered for the area, and may lead to complica... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/18/2025
Locations: Sunnybrook Health Sciences Centre, Toronto, Ontario
Conditions: Zygomaticomaxillary Complex Fracture, Zygomatic Fractures, Zygoma Fracture
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/18/2025
Locations: Akero Clinical Study Site, Birmingham, Alabama +325 locations
Conditions: NASH With Fibrosis, MASH With Fibrosis
Register for Updates
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06179160
Recruiting
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Mayo Clinic Hospital, Phoenix, Arizona +31 locations
Conditions: Solid Tumors, Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC)
Register for Updates
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
NCT06537310
Recruiting
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of RO7567132 as single agent and in combination with atezolizumab. The study will enroll adult participants with selected locally advanced and/or metastatic solid tumors for whom standard therapy does not exist, or has proven to be ineffective or intolerable.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Brown University Health, Providence, Rhode Island +15 locations
Conditions: Cancer-Neoplasms
Register for Updates
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
NCT06107426
Recruiting
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to evaluate how effective ABBV-951 is in treating adult participants with advanced PD in real world setting. ABBV-951 (foslevodopa/foscarbidopa) is an approved drug for the treatment of Parkinson's Disease. The main ROSSINI study... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: University of Alabama at Birmingham - Main /ID# 253477, Birmingham, Alabama +64 locations
Conditions: Parkinson's Disease (PD)
Register for Updates
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
NCT05744921
Recruiting
This study is researching an experimental treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH). The aim of this study is to see how safe and effective the pozelimab + cemdisiran combination is for people with PNH in the long term. The pozelimab + cemdisiran combination may be referred to as "study drugs" in this section. This study is looking at several other research questions, including... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Toronto General Hospital, Toronto, Ontario +35 locations
Conditions: Paroxysmal Nocturnal Hemoglobinuria
Register for Updates
Virtual Reality Distraction for Dental Anxiety (RCT)
NCT06182462
Recruiting
The aim of this randomized clinical trial is to verify the efficacy of VR immersion over a muted cartoon on a wall-mounted TV to decrease dental fear and anxiety of children undergoing dental procedures. The study also aims to gain insight on the satisfaction of parents and healthcare providers on the use of VR during dental appointments. Main research question: Does VR immersion compare to a cartoon on a wall-mounted TV is more efficacious to decrease dental fear and anxiety of children requir... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/18/2025
Locations: St.Justine's Hospital, Montreal, Quebec
Conditions: Dental Anxiety, Dental Phobia, Dental Trauma, Dental Diseases
Register for Updates
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357
Recruiting
The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/18/2025
Locations: Research Site, Scottsdale, Arizona +254 locations
Conditions: Biliary Tract Cancer
Register for Updates
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141
Recruiting
The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Alabama Neurology Associates- Site Number : 8400019, Homewood, Alabama +89 locations
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates